Literature DB >> 12876408

Skin tests and conjunctival and bronchial challenges with extracts of Blomia tropicalis and Dermatophagoides pteronyssinus in patients with allergic asthma and/or rhinoconjunctivitis.

J C García Robaina1, I Sánchez Machín, E Fernández-Caldas, V Iraola Calvo, C Vázquez Moncholi, C Bonnet Moreno, F de la Torre Morín.   

Abstract

BACKGROUND: Blomia tropicalis and Dermatophagoides pteronyssinus are important mite species in Tenerife, Canary Islands, Spain. Several studies have demonstrated a variable degree of allergenic cross-reactivity in vitro. However, only a few have addressed their allergenic cross-reactivity using challenge tests.
OBJECTIVE: The objective of this study was to conduct conjunctival and bronchial challenge tests with B. tropicalis and D. pteronyssinus extracts in a group of 42 patients with allergic asthma and/or rhinoconjunctivitis sensitised to house dust mites (31 females, 11 males; mean age 21.7 +/- 7.02 years).
METHODS: Prick tests using standardised extracts and specific IgE determinations using the CAP system were performed. Bronchial and/or conjunctival challenges were conducted using freeze-dried extracts of both mite species. A patient was considered sensitive to a mite species if she/he had a positive prick and/or CAP test result. A total of 32 conjunctival and 15 bronchial challenges were performed with both mite species.
RESULTS: Prick tests were positive to B. tropicalis in 23 patients (54.7%) and to D. pteronyssinus in 41 (97.6%). One patient (2.4%) was exclusively sensitive to B. tropicalis. The CAP test was positive for B. tropicalis in 28 patients and for D. pteronyssinus in 41. Conjunctival challenges to B. tropicalis were positive in 20 patients (18 sensitised and 2 non-sensitised) and negative in 12 (5 sensitised and 7 non-sensitised patients). Conjunctival challenges with D. pteronyssinus were positive in all 31 D. pteronyssinus-sensitised patients who underwent conjunctival challenges. Bronchial challenges with B. tropicalis were positive in 9 sensitised patients and negative in 6 patients (2 sensitised and 4 non-sensitised). Bronchial challenges with D. pteronyssinus were positive in all patients except 1, who only reacted to B. tropicalis.
CONCLUSIONS: Allergens of the mite species B. tropicalis induce positive conjunctival and bronchial challenges in B. tropicalis-sensitised individuals. Our results suggest that although there is a low to moderate degree of in vivo cross-reactivity between B. tropicalis and D. pteronyssinus, B. tropicalis seems to be a relevant source of allergens in areas where patients are exposed. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12876408     DOI: 10.1159/000071484

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  5 in total

Review 1.  Mite immunotherapy.

Authors:  Enrique Fernández-Caldas; Victor Iraola; Manuel Boquete; Antonio Nieto; Miguel Casanovas
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

Review 2.  Mite allergens.

Authors:  Enrique Fernández-Caldas; Víctor Iraola Calvo
Journal:  Curr Allergy Asthma Rep       Date:  2005-09       Impact factor: 4.806

Review 3.  Particularities of allergy in the Tropics.

Authors:  Luis Caraballo; Josefina Zakzuk; Bee Wah Lee; Nathalie Acevedo; Jian Yi Soh; Mario Sánchez-Borges; Elham Hossny; Elizabeth García; Nelson Rosario; Ignacio Ansotegui; Leonardo Puerta; Jorge Sánchez; Victoria Cardona
Journal:  World Allergy Organ J       Date:  2016-06-27       Impact factor: 4.084

4.  NMR structure and IgE epitopes of Blo t 21, a major dust mite allergen from Blomia tropicalis.

Authors:  Kang Wei Tan; Tan Ching Ong; Yun Feng Gao; Yuen Sung Tiong; Kang Ning Wong; Fook Tim Chew; Yu Keung Mok
Journal:  J Biol Chem       Date:  2012-08-10       Impact factor: 5.157

5.  Conjunctival Provocation Test With Blomia tropicalis.

Authors:  Elizabeth Maria Mercer Mourao; Nelson Augusto Rosario
Journal:  Front Allergy       Date:  2021-05-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.